	US 12,187,778 B2
	Receptors providing targeted costimulation for adoptive cell therapy
John Bridgeman, Manchester (GB); Robert Hawkins, Manchester (GB); Ruben Rodriguez, Dallas, TX (US); and Gray Kueberuwa, Manchester (GB)
Assigned to INSTIL BIO (UK) LIMITED, Manchester (GB)
Filed by INSTIL BIO (UK) LIMITED, Manchester (GB)
Filed on Aug. 30, 2022, as Appl. No. 17/823,223.
Application 17/823,223 is a continuation of application No. 17/843,480, filed on Jun. 17, 2022.
Application 17/843,480 is a continuation of application No. PCT/US2021/042075, filed on Jul. 16, 2021.
Claims priority of provisional application 63/053,494, filed on Jul. 17, 2020.
Prior Publication US 2023/0002470 A1, Jan. 5, 2023
Int. Cl. C07K 14/725 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01); C12N 15/62 (2006.01); C12N 15/86 (2006.01)

CPC C07K 14/7051 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4636 (2023.05); A61K 39/464402 (2023.05); A61K 39/464429 (2023.05); A61K 39/464482 (2023.05); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C12N 5/0636 (2013.01); C12N 15/625 (2013.01); C12N 15/86 (2013.01); A61K 2239/59 (2023.05); C07K 2317/24 (2013.01); C07K 2319/00 (2013.01); C12N 2740/15043 (2013.01)]

13 Claims

1. A chimeric costimulatory antigen receptor (CoStAR) which comprises:

an extracellular binding domain comprising a VH of antibody 196-14 and a VL of antibody 196-14, operatively linked to a transmembrane domain, an intracellular CD28 signaling domain and an intracellular CD40 signaling domain,

wherein the CD28 signaling domain comprises the amino acid sequence of SEQ ID NO: 16, and

wherein the CD40 signaling domain comprises the amino acid sequence of SEQ ID NO: 23,

wherein the CoStAR does not comprise a third intracellular signaling domain.